BMY
BMY clinical trials: BRISTOL MYERS SQUIBB CO
Every trial on ClinicalTrials.gov where BRISTOL MYERS SQUIBB CO is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4,102
- Trials linked
- 2,164
- As lead sponsor
- 1,938
- As collaborator
- 26
- Primary completions as lead sponsor, next 90 days
BMY on the catalyst calendar · BMY registry changes
- Primary completion Jun 13, 2028Sponsor estimatePhase 3NCT06929273A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)Bristol-Myers Squibb · Bipolar Disorder Type I With ManiaRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2027Sponsor estimatePhase 3NCT06140836A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve...Bristol-Myers Squibb · Carcinoma, Non-Small-Cell LungActive, not recruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 6, 2028Sponsor estimatePhase 2NCT07772531A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderBristol-Myers Squibb · Major Depressive DisorderRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2029Sponsor estimatePhase 1/Phase 2NCT07412704A Study of BMS-986528 in Participants With Refractory Rheumatoid ArthritisBristol-Myers Squibb · Arthritis, RheumatoidRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 28, 2027Sponsor estimatePhase 1NCT07171983A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisBristol-Myers Squibb · Rheumatoid ArthritisRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2028Sponsor estimatePhase 3NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseBristol-Myers Squibb · Alzheimer's DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2028Sponsor estimatePhase 3NCT06976203A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Bristol-Myers Squibb · Alzheimer's DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2029Sponsor estimatePhase 3NCT06875310A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With...Mirati Therapeutics Inc. · Carcinoma, Non-Small-Cell LungRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 12, 2031Sponsor estimatePhase 2/Phase 3NCT07063745A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab...Bristol-Myers Squibb · Metastatic Non-small Cell Lung Cancer With MTAP DeletionRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2029Sponsor estimatePhase 3NCT07940777A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy...Bristol-Myers Squibb · Non-obstructive Hypertrophic CardiomyopathyNot yet recruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 29, 2029Sponsor estimatePhase 1/Phase 2NCT07939815A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesBristol-Myers Squibb · Advanced Solid MalignanciesNot yet recruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2028Sponsor estimatePhase 2NCT07415031A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesMirati Therapeutics Inc. · Solid TumorsRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2031Sponsor estimatePhase 3NCT07680790Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in...Bristol-Myers Squibb · Non-Small Cell Lung CancerRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2029Sponsor estimatePhase 3NCT07288567A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)Bristol-Myers Squibb · SchizophreniaRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2027Sponsor estimatePhase 4NCT07221877A Study to Evaluate the Effect of KarXT on Urological SafetyBristol-Myers Squibb · SchizophreniaRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2028Sponsor estimatePhase 2/Phase 3NCT07100080Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small...Bristol-Myers Squibb · Non-Small Cell Lung CancerRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2, 2026Sponsor estimatePhase 3NCT06951711A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)Bristol-Myers Squibb · Bipolar Disorder Type I With Mania or Mania With Mixed FeaturesRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 22, 2029Sponsor estimatePhase 3NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Bristol-Myers Squibb · Alzheimer DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 17, 2027Sponsor estimatePhase 3NCT06646276A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin...Bristol-Myers Squibb · Extensive-Stage Small Cell Lung CancerRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2027Sponsor estimatePhase 3NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With...Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Psychosis Associated With Alzheimer's DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 5, 2023ActualPhase 1/Phase 2NCT04446650A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk...Bristol-Myers Squibb · Primary MyelofibrosisCompletedBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 6, 2029Sponsor estimatePhase 3NCT07285798A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderBristol-Myers Squibb · Irritability Associated With Autism Spectrum DisorderRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 6, 2029Sponsor estimatePhase 3NCT07284745A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismBristol-Myers Squibb · Irritability Associated With Autism Spectrum DisorderRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2030Sponsor estimatePhase 3NCT06561386A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent...Bristol-Myers Squibb · Non-small Cell Lung CancerRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 8, 2030Sponsor estimatePhase 3NCT07424404A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders...Karuna Therapeutics, Inc., a Bristol Myers Squibb company · SchizophreniaRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4,077 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner